{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'basis of this trial, larger randomized studies have been launched to further evaluate PARP', 'inhibitors in men with CRPC.', 'A', 'Response to Olaparib', 'No Response to Olaparib', 'Patient No.', '17', '15', '14', '20', '30', '39', '35', '36', '1', '6', '5', '26', '48', '8', '16 11', '7', '12', '44', '31', '50', '2', '3', '4', '9', '110', '13', '31819212223242527', '28', '29', '32', '33', '34', '37', '40', '4)', '42', '43', '45', '46', '47', '49', 'Time on', '24', '36', '36', '48', '>44', '>44', '>40', '57', '73', '16', '58', '19', '39', '62', '>40', '12', '12', '11', '24', '8', '8', '24', '8', '7', '11', '13', '12', '1', '12', '7', '12', '4', '12', '12', '22', '13', '4', '12', '17', '4', '12', '11', '12', '12', '9', '12', '12', '1', '12', 'Treatment', '(wk)', 'Biomarker', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Positive', 'BRCA2', '*', '*', 'ATM', 'FANCA', 'CHEK2', 'BRCA1', 'PALB2', 'HDAC2', 'RAD51', 'MLH3', 'ERCC3', 'MRE11', 'NBN', 'Frameshift mutation', 'Single copy deletion', 'Missense mutation', 'Germline event', 'Stop gain', 'Homozygous deletion', 'Copy-neutral loss of heterozygosity', 'B', 'Radiologic Progression-free Survival', 'Overall Survival', '1.00', '1.00', 'P<0.001 by log-rank test', 'P=0.05 by log-rank test', '0.75', '0.75', 'Biomarker-positive,', 'Biomarker-positive,', 'median: 13.8 mo', 'median: 9.8 mo', '0.50', '0.50', 'Biomarker-negative,', '0.25', 'Biomarker-negative,', '0.25', 'median: 7.5 mo', 'median: 2.7 mo', '0.00', '0.00', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '0', '1', '2', '3', '4', '5', '6', '7', '8', '9 10 11 12 13 14 15 16 17 18 19 20', 'Months since Trial Entry', 'Months since Trial Entry', 'No. at Risk', 'No. at Risk', 'Biomarker- 33 33 26 7 6 6 2 2 2 1 1 1 1 1 1 1 1 1 1 0 0', 'Biomarker- 33 33 31 27 24 21 18 16 13 11 7 6 4 4 4 4 3 3 3 2 2', 'negative', 'negative', 'Biomarker- 16 16 16 14 14 13 12 12 12 7 6 5 5 5 2 2 2 2 1 0 0', 'Biomarker- 16 16 16 16 16 15 15 14 13 13 10 6 5 5 4 3 2 2 1 0 0', 'positive', 'positive', 'No. of Events', 'No. of Events', 'Biomarker- 0 7 17 1 0 4 0 0 1 0 0 0 0 0 0 0 0 0 0 0', 'Biomarker- 0 2 4 2 3 3 1 211120001001 0 -', 'negative', 'negative', 'Biomarker- 0 0 2 0 1 1 0 0 2 1 1 0 0 2 0 0 0 0 0', '0', 'Biomarker- 0 0 0 0 1 0 0 1 0 1 2 0 0 1 0 1 0 2 0 0 -', 'positive', 'positive', 'Figure 10: Results from the Phase II TOPARP Trial [88]. Patients with metastatic, castration-', 'resistant prostate cancer were treated with olaparib tablets at a dose of 400 mg twice a day. (A)', 'Responses to olaparib were enriched in patients with biallelic loss of DNA repair genes. Radiographic', 'PFS (B) and overall survival (C) were significantly longer in patients with biallelic loss of DNA repair', 'genes (i.e., biomarker-positive).', 'In 2020, olaparib was approved as treatment for mCRPC patients who have progressed on', 'prior abiraterone or enzalutamide on the basis of the Phase III PROfound study[93].', \"PROfound was a randomized, open-label study evaluating olaparib VS. physician's choice of\", '22(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'enzalutamide or abiraterone in men with mCRPC and deleterious germline or somatic', 'mutations in HR repair genes. Enrollment was allowed on the basis of a panel of genes', 'involved in the HR repair pathway. The primary endpoint was progression free survival (PFS)', 'in the group with BRCA1, BRCA2 and/or ATM mutations (Cohort A). A second cohort', 'consisted of patients with mutations in other HR repair-associated genes (Cohort B).', 'Secondary endpoints were analyzed in a hierarchical fashion to control for trial-wide type 1', 'error associated with multiple testing, which occurred in the following order: objective', 'response rate (Cohort A), PFS (combined Cohorts A and B), time to pain progression (Cohort', 'A), and overall survival (Cohort A).', 'The primary endpoint was met, with a PFS of 7.4 months VS. 3.6 months (P<0.001) in the', 'olaparib VS. control groups for Cohort A. Secondary endpoints also favored the olaparib', 'group, with an objective response rate in Cohort A of 33% vs. 2% in control group (P<0.001),', 'median PFS of 5.8 months VS. 3.5 months for combined Cohorts A and B (P<0.001), median', 'overall survival of 18.5 months vs. 15.1 months for Cohort A (P=0.02) and median overall', 'survival of 17.5 months VS. 14.3 months for combined Cohorts A and B (P=0.0063). These', 'results led the FDA to approve olaparib for mCRPC patients with somatic or germline', 'alterations in ATM, BRCA1, BRCA2, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL,', 'PALB2, RAD51B, RAD51C, RAD51D and/or RAD54L.', 'Of note, PARP inhibitors have also been shown across multiple preclinical tumor models to', 'potentiate the antitumor effects of DNA damaging cytotoxic agents (e.g. alkylating agents,', 'platinum chemotherapy) as well as radiation [72, 75-78]. Importantly, these effects were not', 'restricted to cell lines with biallelic loss of DNA damage pathway genes. Proof of concept for', 'combining PARP inhibitors with DNA damaging agents is provided by the I-SPY 2 TRIAL.', 'This study was a multi-center, randomized, Phase II \"platform\" trial testing multiple', 'experimental regimens added to a control \"backbone\" regimen. Patients with high-risk', 'primary breast cancer planning to undergo surgery were eligible to receive neoadjuvant', 'therapy per protocol [89]. The control arm consisted of 12 weekly cycles of paclitaxel', 'followed by 4 cycles, every 2-3 weeks of doxorubicin plus cyclophosphamide. One of the', 'experimental arms combined the PARP inhibitor veliparib 50 mg by mouth twice daily and', 'carboplatin AUC 6 concurrently with the weekly paclitaxel. The primary endpoint was', 'pathologic complete response (pCR) rate as assessed at the time of surgery. In the subset of', 'patients with triple negative breast cancer (i.e. HER2 negative, ER/PR negative), the estimated', 'rate of pCR was 51% (95% Bayesian probability interval [PI], 36 to 66%) in the veliparib-', 'carboplatin arm compared to 26% (95% PI, 9 to 43%) in the control group. This translated to', 'an 88% predicted probability of success in the Phase III setting. Importantly, this study was', 'not restricted to patients with loss of DNA repair pathway genes, however, it was noted that', 'more patients in the veliparib-carboplatin arm (12/72, 17%) had deleterious mutations in', 'BRCAI or BRCA2 compared to control (2/44, 5%). Several other studies testing olaparib in', 'combination with DNA damaging therapies are underway or have recently completed. The', 'results of these studies generally support combining PARP inhibitors with DNA damaging', '23(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}